BCWM
BMRN icon

Bartlett & Co Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bartlett & Co Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6
Closed -$501 – 955
2021
Q2 		$501 Hold
6
– – ﹤0.01% 1023
2021
Q1 		$453 Hold
6
– – ﹤0.01% 1057
2020
Q4 		$526 Buy
+6
New +$476 ﹤0.01% 1140

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bartlett & Co Wealth Management's BMRN Position: Q3 2021 in Review

Bartlett & Co Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 6 shares — an estimated $501 sold.

Bartlett & Co Wealth Management first reported a position in BMRN in Q4 2020 and held it in 3 quarters. The position peaked at $526 in Q4 2020. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

  • Bartlett & Co Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bartlett & Co Wealth Management sold 6 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $501.
  • Bartlett & Co Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Bartlett & Co Wealth Management's BioMarin Pharmaceuticals position peaked at $526 in Q4 2020.
  • 511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Bartlett & Co Wealth Management's 13F filing for Q3 2021, filed 14 Feb 2024.